Vascular endothelial growth factor (VEGF)-A promotes tumor-associated angiogenesis, and the monoclonal antibody that targets VEGF, bevacizumab, can potentially target both tumor-promoting angiogenesis and enhance immunotherapy. The gene discussed is VEGFA; the disease is neoplasm.